116 related articles for article (PubMed ID: 6288240)
1. Yoshi 864 plus medroxyprogesterone acetate in adenocarcinoma of the kidney: A Southwest Oncology Group Study.
Altman SJ; Stephens RL; Bonnet JD
Cancer Treat Rep; 1982 Sep; 66(9):1781-2. PubMed ID: 6288240
[No Abstract] [Full Text] [Related]
2. Phase II study of medroxyprogesterone acetate with tamoxifen in advanced renal cell cancer.
Fuks JZ; Aisner J; Van Echo DA; Wiernik PH
Cancer Treat Rep; 1982 Sep; 66(9):1773-4. PubMed ID: 7116354
[No Abstract] [Full Text] [Related]
3. Advanced adenocarcinoma of the kidney: therapy with lomustine, vinblastine, hydroxyurea, and medroxyprogesterone acetate and regression analysis of factors relating to survival.
Brubaker LH; Troner MB; Birch R
Cancer Treat Rep; 1983; 67(7-8):741-2. PubMed ID: 6223695
[No Abstract] [Full Text] [Related]
4. High-dose medroxyprogesterone acetate in patients with renal adenocarcinoma and measurable lung metastases: a phase II study.
Kjaer M; Frederiksen PL
Cancer Treat Rep; 1986 Mar; 70(3):431-2. PubMed ID: 2937534
[No Abstract] [Full Text] [Related]
5. Phase II clinical trial of mitoxantrone in patients with advanced renal cell carcinoma: a Southwest Oncology Group study.
Taylor SA; Von Hoff DD; Baker LH; Balcerzak SP
Cancer Treat Rep; 1984 Jun; 68(6):919-20. PubMed ID: 6733708
[No Abstract] [Full Text] [Related]
6. [the oral use of a progestational hormone (Provera 100) as an adjuvant in therapy of adenocarcinoma of the kidney. Preliminary report].
Liberti M; Di Silverio F; Concolino G; Tenaglia R; Marocchi A
Minerva Urol; 1980; 32(3):175-8. PubMed ID: 7432332
[TBL] [Abstract][Full Text] [Related]
7. Endocrinological effects of treatment with high doses of medroxyprogesterone acetate in patients with renal or prostatic adenocarcinoma.
Tomic R; Ljungberg B; Damber JE
Scand J Urol Nephrol Suppl; 1988; 110():185-7. PubMed ID: 2973122
[No Abstract] [Full Text] [Related]
8. Phase II trial of dianhydrogalactitol in advanced renal cell carcinoma: a Southwest Oncology Group study.
Ratanatharathorn V; Baker LH; Balducci L; Talley RW; Hoogstraten B
Cancer Treat Rep; 1982 May; 66(5):1231-2. PubMed ID: 7083224
[No Abstract] [Full Text] [Related]
9. Phase II clinical study of Yoshi 864 in squamous cell carcinoma of the uterine cervix.
Slavik M; Muss H; Blessing JA
Cancer Treat Rep; 1983 Feb; 67(2):195-6. PubMed ID: 6297730
[No Abstract] [Full Text] [Related]
10. Phase II study of vinblastine-CCNU, triazinate, and dactinomycin in advanced renal cell cancer.
Hahn RG; Begg CB; Davis T
Cancer Treat Rep; 1981; 65(7-8):711-13. PubMed ID: 7018680
[TBL] [Abstract][Full Text] [Related]
11. [Hormone therapy in renal adenocarcinoma].
Giuliani L; Pescatore D; Giberti C
Minerva Chir; 1977 Dec 15-31; 32(23-24):1463-5. PubMed ID: 600435
[No Abstract] [Full Text] [Related]
12. High-dose medroxyprogesterone acetate (MPA) in advanced chemotherapy-resistant ovarian carcinoma: a phase II study.
Aabo K; Pedersen AG; Haid I; Dombernowsky P
Cancer Treat Rep; 1982 Feb; 66(2):407-8. PubMed ID: 6459846
[No Abstract] [Full Text] [Related]
13. [A new method for administering cytostatics. Preliminary evaluation in 7 cases of adenocarcinoma of the kidney].
Escudero Barrilero A; Mateos Torres A; Maganto Pavón E; Mayayo Dehesa R; Allona Almagro A; Zubicoa Ezpeleta S; García González R
Arch Esp Urol; 1984 Dec; 37 Suppl 1():593-605. PubMed ID: 6543489
[No Abstract] [Full Text] [Related]
14. Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic or recurrent endometrial carcinoma. Preliminary report.
Piver MS; Lele S; Barlow JJ
Obstet Gynecol; 1980 Sep; 56(3):370-2. PubMed ID: 7422177
[TBL] [Abstract][Full Text] [Related]
15. [Regressions of pulmonary metastases of clear cell carcinoma after nephrectomy and progestogen therapy].
Frea B; Tizzani A; Tasso M
Minerva Urol; 1981; 33(2):97-101. PubMed ID: 7322102
[No Abstract] [Full Text] [Related]
16. Effect of medroxyprogesterone acetate and doxorubicin on sublines of 13762 mammary adenocarcinoma in rats.
Formelli F; Zaccheo T; Casazza AM; Bellini O; Di Marco A
Eur J Cancer Clin Oncol; 1981 Nov; 17(11):1211-21. PubMed ID: 6460631
[No Abstract] [Full Text] [Related]
17. Phase II study of continuous 5-day vinblastine infusion in renal adenocarcinoma.
Kuebler JP; Hogan TF; Trump DL; Bryan GT
Cancer Treat Rep; 1984 Jun; 68(6):925-6. PubMed ID: 6733709
[No Abstract] [Full Text] [Related]
18. Treatment of metastatic renal cell carcinoma: review of experience and world literature.
Luderer RC; Opipari MI; Perrotta AL
J Am Osteopath Assoc; 1978 Apr; 77(8):590-603. PubMed ID: 649445
[No Abstract] [Full Text] [Related]
19. Phase II trial of spirogermanium in advanced renal cell carcinoma: a Cancer and Leukemia Group B study.
Schulman P; Davis RB; Rafla S; Green M; Henderson E
Cancer Treat Rep; 1984 Oct; 68(10):1305-6. PubMed ID: 6525606
[No Abstract] [Full Text] [Related]
20. Combination of vinblastine and bleomycin in metastatic renal cell carcinoma.
Knost JA; Oldham RK; Hande KR; Rhamy RK; Greco FA
Cancer Treat Rep; 1981; 65(3-4):349-50. PubMed ID: 6165469
[No Abstract] [Full Text] [Related]
[Next] [New Search]
